Viking Therapeutics (NASDAQ: VKTX) has captured the financial world’s attention with its stock quadrupling in 2024, fueled by groundbreaking clinical trials for its obesity drug, VK2735. As it eyes market leadership with a potential quadruple agonist therapy, Viking is setting the stage for an epic showdown with pharmaceutical titans like Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) in the rapidly expanding metabolic disorders arena.
In the high-stakes world of biopharmaceuticals, a once-little-known company, Viking Therapeutics, has burst onto the scene, transforming from a “penny stock” to a mid-cap marvel. Its stock surged by approximately 300% in 2024, making it the top gainer among U.S.-listed mid-cap stocks. This meteoric rise is largely attributed to its innovative approach to metabolic and endocrine disorders, particularly its highly anticipated weight-loss drug, VK2735, which analysts believe could be a game-changer in a market projected to exceed $100 billion by 2030, as reported by The Motley Fool.
The company, with its lean team of just 48 full-time employees, is now seen as a formidable challenger to established pharmaceutical giants. Wall Street’s sentiment is overwhelmingly bullish, with all eight analysts who have recently weighed in on Viking Therapeutics assigning a “buy” rating, some setting price targets as high as $138, according to analyst insights shared in a recent article on Nasdaq.
Viking’s Vanguard in Weight Management: VK2735’s Dual Promise
At the heart of Viking’s burgeoning reputation is VK2735, a dual agonist of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This mechanism mirrors that of Eli Lilly’s blockbuster drug, Mounjaro (tirzepatide), which has set new standards in weight loss. Viking is developing VK2735 in both injectable and oral formulations, aiming for broad market penetration.
The injectable version of VK2735 showcased impressive efficacy in its Phase 2 VENTURE trial, achieving up to a 13.1% placebo-adjusted mean weight loss after just 13 weeks of treatment. Equally promising were the early results for the oral formulation, which demonstrated up to a 3.3% mean weight loss in a 28-day multiple ascending dose (MAD) study, with initial Phase 1 results showing significant weight reductions up to 7.8% relative to baseline, and 6% better than placebo, as noted by Viking Therapeutics in February 2023.
Beyond efficacy, VK2735 has demonstrated an encouraging safety and tolerability profile. Compared to other GLP-1 drugs, it exhibited a low incidence of gastrointestinal (GI) adverse effects, a critical factor for patient adherence and a potential competitive advantage. While high doses of the oral version did lead to some study discontinuations due to adverse reactions, the 12.2% mean weight loss observed at the highest dose in 13 weeks suggests that dose titration strategies could mitigate tolerability challenges and maximize commercial viability.
Beyond Dual Agonism: The Quadruple Threat
What truly excites investors and analysts alike is Viking’s audacious plan to combine VK2735 with an early-stage dual amylin and calcitonin therapy. This ambitious strategy aims to create a “quadruple agonist” – an entirely novel approach to weight management that mimics the action of four key hormones: GLP-1, GIP, amylin, and calcitonin. If successful, this could unlock unprecedented levels of efficacy, potentially leapfrogging even Eli Lilly’s investigational triple agonist, retatrutide, as highlighted by The Motley Fool.
While this quadruple agonist is still in its nascent stages, with an Investigational New Drug (IND) application planned for submission to the FDA by year-end, it underscores Viking’s commitment to innovation and its bold vision for dominating the weight management landscape. This forward-thinking strategy positions Viking not just as a competitor, but as a potential innovator redefining the future of obesity treatment.
Diversifying the Portfolio: Tackling MASH and Muscle Wasting
Viking Therapeutics’ investment appeal extends beyond obesity, with a diversified pipeline addressing other significant metabolic and endocrine disorders. Its drug candidate, VK2809, a novel liver-selective thyroid hormone receptor beta agonist, recently delivered positive top-line results from its Phase 2b Voyage study in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH), now commonly referred to as metabolic dysfunction-associated steatohepatitis (MASH).
The study successfully achieved its primary endpoint, demonstrating statistically significant reductions in liver fat content, with up to 85% of patients receiving VK2809 experiencing at least a 30% relative reduction. This level of reduction is strongly associated with a greater likelihood of histologic response in MASH. VK2809 also showed significant reductions in LDL-C, triglycerides, and atherogenic lipoproteins, addressing multiple facets of this complex disease, as detailed in a Ligand Pharmaceuticals press release.
Another promising candidate is VK 5211, a selective androgen receptor modulator (SARM), in development for patients recovering from non-elective hip fracture surgery and muscle wasting. In a Phase 2 proof-of-concept trial, VK 5211 demonstrated statistically significant, dose-dependent increases in lean body mass, appendicular lean body mass, and total lean body mass compared to placebo. It also showed numerical improvements in functional performance assessments and a favorable safety profile, with no drug-related serious adverse events reported, according to results presented at the American Society for Bone and Mineral Research (ASBMR) 2018 annual meeting.
Hip fractures represent a significant medical challenge, hospitalizing over 300,000 older people annually in the U.S. and carrying a 1-year mortality rate of approximately 21%, as cited by the CDC. With no currently approved therapies specifically for restoring lean body mass, bone mineral density, or physical function post-hip fracture, VK 5211 addresses a crucial unmet medical need, demonstrating the breadth of Viking’s therapeutic focus.
The Investment Thesis: High Stakes, Higher Rewards
For investors navigating the biotech landscape, Viking Therapeutics presents a classic high-risk, high-reward scenario. While the company’s compact size and reliance on a few key pipeline candidates inherently carry more risk than a diversified giant like Eli Lilly, the upside potential is immense. The unanimous “buy” ratings from Wall Street analysts and the rapid appreciation of its stock reflect confidence in its scientific innovation and market positioning.
The global obesity epidemic continues to worsen, with the World Health Organization (WHO) reporting that adult obesity has more than doubled since 1990, impacting 16% of adults globally. This escalating health crisis fuels a massive and growing demand for effective weight management solutions, creating a fertile ground for companies like Viking. If Viking’s drug candidates continue to demonstrate strong efficacy and safety through later-stage trials, the company is poised to capture a substantial share of this burgeoning market.
Looking Ahead: What Investors Should Watch
As Viking Therapeutics marches forward, investors will keenly watch several key milestones:
- The initiation of a Phase 2 trial for oral VK2735 in the second half of 2024, which is expected to feature longer treatment periods and potentially higher doses to achieve greater weight loss.
- The progression of the injectable VK2735 into Phase 3 studies, a critical step towards potential market approval.
- The submission of the Investigational New Drug (IND) Application for its early-stage dual amylin and calcitonin therapy by year-end, paving the way for human clinical trials and the eventual development of the highly anticipated quadruple agonist.
- Further data readouts for VK2809 in MASH, particularly as it moves towards a potential Phase 3 trial initiation, which would trigger a $10 million milestone payment to partner Ligand Pharmaceuticals.
For those comfortable with above-average risk, Viking Therapeutics offers an compelling investment opportunity. Its innovative pipeline, coupled with strong early clinical data and a bullish market outlook, positions it as a company to watch closely in the evolving battle against metabolic disorders.
